All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells wherever they reside.

The idea behind the company’s T-SIGn platform is that by delivering to tumor cells genes that interplay with immuno-oncology pathways, the company can either weaponize the cells to modify the tumor microenvironment or alter their properties to make them more vulnerable to immune attack...